Orthocell Wins Approval for Nerve Repair Device Across US Military, VA Hospital Networks

MT Newswires Live
04/15

Orthocell (ASX:OCC) said it has secured approval for its Remplir nerve repair device to be used across the US Department of Defense and Veterans Affairs hospital networks, according to a Wednesday Australian bourse filing.

The company said it will use its existing US distributor network to target military and VA surgeons operating within these hospital systems, which currently covers 17 states.

The approval comes as Orthocell said it is seeing growing evidence of increasing commercialization and revenue momentum in the US market.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10